Kettering Health and Telix Pharmaceuticals have signed a deal to study Telix's investigational prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical, illuccix.
Kettering and Telix will study illuccix, a radiotracer based on gallium-68 (Ga-68) PSMA-11 for diagnostic imaging with PET and lutetium-177 (Lu-177) PSMA for radioligand therapy. Also, the collaboration establishes Kettering Health as a regional center of excellence for PET molecular imaging and theranostics, with an initial focus on the diagnosis and treatment of prostate cancer, according to their memorandum of understanding.
Kettering Health is headquartered at the Kettering Memorial Hospital in Ohio and includes a network of 13 hospitals, emergency centers, and outpatient facilities.
